Early isolated central nervous system relapse of mantle cell lymphoma successfully treated with ibrutinib and CAR T-cell therapy

Česká verze

Authors: A. Hrušková; R. Szotkowská; T. Papajík; A. Obr
Authors place of work: Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc
Published in the journal: Transfuze Hematol. dnes,31, 2025, No. 4, p. 311-315.
Category: Kazuistiky
doi: https://doi.org/10.48095/cctahd202526

Summary

Mantle cell lymphoma (MCL) is a relatively rare and clinically distinct subtype of non-Hodgkin lymphoma. Involvement of the central nervous system is an uncommon manifestation at both diagnosis and recurrence. Central nervous system (CNS) relapse more frequently occurs in the context of aggressive disease behaviour and portends a poor prognosis. However, advances in therapeutic strategies for MCL have opened the possibility of achieving durable remission, even in this high-risk presentation. We report a case of a patient who developed an early, isolated CNS relapse following autologous stem cell transplantation. The patient was successfully treated with a sequential treatment protocol combining chemoimmunotherapy, ibrutinib and chimeric antigen receptor T-cell therapy.

Keywords:

mantle cell lymphoma – ibrutinib – CNS involvement – CAR T-cell therapy

Zdroje

1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36 (7): 1720–1748. doi: 10.1038/s41375-022 -⁠ 01620-2.

2. Silkenstedt E, Linton K, Dreyling M. Mantle cell lymphoma –⁠ advances in molecular biology, prognostication and treatment approaches. Br J Haematol. 2021; 195 (2): 162–173. doi: 10.1111/bjh.17419.

3. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009; 27 (4): 511–518. doi: 10.1200/JCO.2008. 16.8435.

4. Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016; 175 (3): 410–418. doi: 10.1111/ bjh.14241.

5. Hermine O, Rule S, Forstpointner R, et al. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized Mantle Cell Lymphoma Younger trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2023; 41 (3): 479–484. doi: 10.1200/JCO.22.01780.

6. Cheah CY, George A, Gine E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013; 24 (8): 2119–2123. doi: 10.1093/annonc/ mdt139.

7. Trab T, Møller MB, Pedersen MO, et al. Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): characteristics and risk factors in a Danish nationwide population-based study. Br J Haematol. 2025; 207 (4): 1366–1376. doi: 10.1111/bjh.70082.

8. McLaughlin N, Gao J, Goyal G, et al. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023; 64 (2): 371–377. doi: 10.1080/10428194.2022.2148211.

9. Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma. 2013; 54 (9): 1908–1914. doi: 10.3109/10428194.2013.767454.

10. Alderuccio JP, Nayak L, Cwynarski K. How I treat secondary CNS involvement by aggressive lymphomas. Blood. 2023; 142 (21): 1771–1783. doi: 10.1182/blood.2023020168.

11. Bernard S, Goldwirt L, Amorim S, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015; 126 (14): 1695–1698. doi: 10.1182/blood-2015-05-647834.

12. Ryan CE, Keane C, Khot A, et al. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. Br J Haematol. 2023; 203 (5): 774–780. doi: 10.1111/bjh.19037.

13. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32 (27): 3059–3067. doi: 10.1200/JCO.2013.54.8800.

14. Common Terminology Criteria for Adverse Events (CTCAE). [Internet]. U.S. Department of Health and Human Services. [Accessed 2025 Oct 7]. Available from: https: //ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

15. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25 (4): 625–638. doi: 10.1016/j.bbmt.2018.12.758.

16. Rejeski K, Roddie C, Bachmeier C, et al. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023; 142 (10): 865–877. doi: 10.1182/blood.202302 0578.

17. Rusconi C, Dreyling M, Zucca E, et al. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022; 140 (17): 1907–1916. doi: 10.1182/blood.2022015560.

18. Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G, Rule SA. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement –⁠ a multi-centre case series from the United Kingdom. Br J Haematol. 2017; 178 (2): 327–329. doi: 10.1111/bjh.14122.

19. Oh TS, Burkart M, Behdad A, Savas H, Karmali R. Ibrutinib plus R-ICE induces remission in blastoid variant mantle cell lymphoma with CNS relapse. Case Rep Hematol. 2022; 2022 : 1930546. doi: 10.1155/2022/1930546.

20. Barrett A, Lowe J, Carroll A, et al. Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib: case report. eJHaem. 2023; 5 (1): 238–241. doi: 10.1002/jha2.830.

21. Peyrl A, Chocholous M, Azizi AA, et al. Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. J Neurooncol. 2014; 120 (1): 139–145. doi: 10.1007/s11060-014-1531-1.

22. Wang Y, Jain MD, Xu ML, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023; 41 (14): 2594–2606. doi: 10.1200/JCO.22.01797.

23. Ahmed G, Nastoupil LJ, Jain MD, et al. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024; 8 (13): 3528–3531. doi: 10.1182/bloodadvances.2023012255.

24. Wang M, Munoz J, Goy A, et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024; 42 (10): 1146–1157. doi: 10.1200/JCO.23.02214.

25. Liebers N, Bachmeier C, Bettac L, et al. Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma. Blood Cancer Discov. 2025; 6 (3): 182–190. doi: 10.1158/2643-3230.BCD-24-0178.

AUTHOR CONTRIBUTIONS

A.H. –⁠ main author of manuscript, attending physician

A.O. –⁠ major revisions of the manuscript

R.S. –⁠ minor revisions of the manuscript, attending physician

T.P. –⁠ minor revisions of the manuscript

All authors read and approved the final manuscript.

CONFLICT OF INTEREST

The authors declared no potential conflicts of interest with respect to authorship and publication of this article.

ACKNOWLEDGMENT

We would like to thank Mgr. Pavel Kurfürst for language proofreading of the manuscript and constructive comments.

FUNDING

Supported by IGA_LF_2025_005, MH CZ –⁠ DRO (FNOl, 00098892).